Formulary guidance and transparency from P&T to point of care


Reality Check on Psoriatic Arthritis

Market access for psoriatic arthritis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 74% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In April 2019, the FDA approved Samsung Bioepis Co., Ltd.'s Eticovo (etanercept-ykro) for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis in people at least four years old, psoriatic arthritis and polyarticular juvenile idiopathic arthritis in children at least two years old
  • Key Findings: Manufacturers with franchises across indications often hold contracting power and improved position, which is everything in this market. In terms of contracting, Humira is the product to beat, and Enbrel battles for the second place.

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.